Welcome to our dedicated page for Pharmacyte Biotech SEC filings (Ticker: PMCB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PharmaCyte Biotech, Inc. filings document the company's public-company reporting, capital structure and governance as a Nasdaq-listed biotechnology issuer with common stock registered under PMCB. Recent disclosures include 8-K material-event reports, proxy statements for stockholder votes, equity incentive plan amendments, securities issuance authorizations, preferred stock and warrant financing terms, and notices related to periodic reporting.
The filings also document material agreements tied to external investments and capital deployment, alongside shareholder voting mechanics and security-structure disclosures for common stock, convertible preferred stock and warrants.
PharmaCyte Biotech, Inc. reported that director Robert Weinstein received a grant of stock options covering 119,170 shares of common stock. The options have an exercise price of $0.67 per share, were awarded at no cost, and expire on March 30, 2036. They will vest in full on the date of the company’s next annual meeting of stockholders, subject to his continued service.
PharmaCyte Biotech, Inc. director Wayne Remell Walker received a grant of stock options covering 119,170 shares of common stock. The options have an exercise price of $0.67 per share and expire on March 30, 2036, with 119,170 derivative securities held after this grant.
According to the filing, the options will vest in full on the date of the company’s next annual meeting of stockholders, subject to Mr. Walker’s continued service. This award is characterized as a grant or other acquisition of derivative securities rather than an open-market purchase.
PharmaCyte Biotech director Jonathan Schechter received a grant of stock options for 119,170 shares of Common Stock. The options have a $0.67 exercise price, expire on March 30, 2036, and were awarded as compensation, not an open-market purchase. They vest in full at the issuer's next annual stockholder meeting, subject to his continued service, leaving him with 119,170 options following this grant.
PharmaCyte Biotech, Inc. director Michael M. Abecassis received a grant of stock options covering 119,170 shares of common stock. The options have an exercise price of $0.67 per share and expire on March 30, 2036. According to the terms, the options vest in full on the date of the company’s next annual meeting of stockholders, subject to his continued service.
PharmaCyte Biotech, Inc. reported results of its annual stockholder meeting held by webcast. Stockholders approved all five proposals, including an amendment to the 2022 Equity Incentive Plan that increases the shares of common stock available for awards by 2,000,000.
Five directors were elected to serve until the next annual meeting, each receiving over 3.3 million votes in favor, with broker non-votes recorded. Stockholders also ratified CBIZ CPAs P.C. as independent auditor for the fiscal year ending April 30, 2026.
Investors approved, on a non-binding advisory basis, the compensation of the named executive officers. They further authorized the board, but did not require it, to implement a reverse stock split of the outstanding common stock at any ratio between 1-for-1.1 and 1-for-100.
PharmaCyte Biotech, Inc., identified as a ten percent owner of FEMASYS INC, filed a Form 4 related to FEMASYS common stock. The provided data show no reported purchases, sales, or derivative exercises, with all transaction counters and share amounts recorded as zero.
PharmaCyte Biotech, Inc. reports beneficial ownership of 4,932,825 shares of Femasys Inc. common stock, representing 7.87% of the class based on 58,479,824 shares outstanding as of November 13, 2025.
The filing states the position includes 695,537 currently held shares and Series A warrants exercisable for 4,237,288 shares (subject to a 19.99% beneficial ownership limitation); percentage was calculated using the issuer's reported outstanding shares plus the warrants.
PharmaCyte Biotech, Inc. reports beneficial ownership of 4,932,825 shares of Femasys Inc. common stock, representing 7.87% of the class based on 58,479,824 shares outstanding as of November 13, 2025.
The filing states the position includes 695,537 currently held shares and Series A warrants exercisable for 4,237,288 shares (subject to a 19.99% beneficial ownership limitation); percentage was calculated using the issuer's reported outstanding shares plus the warrants.
PharmaCyte Biotech reported financial results for the three and nine months ended January 31, 2026, as it continues developing its Cell-in-a-Box-based cancer therapies while its pancreatic cancer program remains on FDA clinical hold. The company generated no revenue, reflecting its development-stage status.
For the quarter, PharmaCyte recorded net income of $746,860, driven mainly by fair value gains on investments and warrant-related items, but a net loss attributable to common stockholders of $1.56 million, or $0.17 per share, after preferred stock accretion and dividends. For the nine months, the loss attributable to common stockholders was $18.33 million, or $2.41 per share.
As of January 31, 2026, the company held $20.2 million in cash and cash equivalents and total assets of $55.9 million, including sizable fair value investments in Femasys and Q/C Technologies preferred shares and warrants. Stockholders’ equity declined to $38.1 million, while warrant and derivative liabilities increased to $14.8 million, reflecting the liability classification of these instruments.
Operating cash outflow for the nine months was $3.76 million, partly offset by $2.0 million of net investing inflows and $6.75 million of financing inflows from the August 2025 Series C convertible preferred stock and warrant financing and warrant exercises. Management states that current cash is expected to fund projected operating requirements for at least twelve months, but additional capital will be needed to complete a pancreatic cancer clinical trial and broader development plans, and equity or debt financing could be dilutive or restrictive.
PharmaCyte Biotech, Inc. is holding a virtual annual stockholder meeting on March 30, 2026 to vote on key corporate matters. Stockholders will elect five directors, ratify CBIZ CPAs P.C. as independent auditor, and cast an advisory vote on executive compensation.
They will also vote on a reverse stock split of common stock at a ratio between 1‑for‑1.1 and 1‑for‑100, and on amending the 2022 Equity Incentive Plan to increase shares available for awards by 2,000,000. The board recommends approval of all proposals.